Business
biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain
biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n \n biOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain\n \n \nbiOasis Releases Quantitative Results: siRNA-Transcendpep Reduces Target Gene Expression in the Brain\n\nThe Ability to Deliver siRNAs to the Brain Represents a Major Advancement in the Potential Treatment of CNS Disorders by Modifying Expression of Disease-Causing Genes - Results from initial experiments show modification of gene expression by 40% to 50%\n\n \n VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 25, 2014) - BIOASIS TECHNOLOGIES INC. (TSX VENTURE:BTI)(OTCQX:BIOAF), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announced on May 6th, 2014, that its newly discovered carrier peptide-Transcendpep-effectively delivered siRNA across the BBB and into brain cells. The company announces that it has achieved effective knock-down of the expression of a target gene in the brain in a sequence-specific manner. Independent analysis of brain tissue revealed that, not only did Transcendpep deliver the siRNA to the brain tissue, but it also reduced the expression of the target gene by 40% to 50% after a single dose. \n \"Injection of a small bioconjugate of siRNA coupled to Transcendpep achieved a significant reduction in target gene expression in the brain,\" says Dr. Wilfred Jefferies, Founding Scientist of biOasis. \"This represents a potential advancement for reducing disease-associated gene expression that often leads to the pathology present in a variety of brain diseases.\" \n \"These findings expand the preeminent standing of biOasis in the area of BBB carriers and provides vast opportunities for Transcendpep to act as a platform to significantly advance the treatment of brain diseases,\" says Rob Hutchison, CEO. \"Due to the vast market potential of siRNA delivery to the brain, we are focused on advancing this program to the IND stage and commencing Phase I Clinical Trials as soon as possible. This adds to biOasis' development programs in the delivery of therapeutics across the BBB, which includes our metabolic disease programs for lysosomal storage diseases such as Hunter Syndrome and Sandhoff Disease and our oncology program (Transcendpep-Herceptin©) for the treatment of brain metastases of HER2+ breast can...